Novel α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type: Chemical synthesis, in vitro characterization, and in vivo prevention of acute neurodegeneration

Journal of Medicinal Chemistry

Volumn 48, Issue 14, 2005, Pages 4618-4627

  Elger, Bernd ^a   Huth, Andreas ^a   Neuhaus, Roland ^a   Ottow, Eckard ^a   Schneider, Herbert ^a   Seilheimer, Bernd ^a   Turski, Lechoslaw ^b  

^a BAYER PHARMA AG   (Germany)

^b Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 2,3 DIMETHYL 6 PHENYL 12H 1,3 DIOXOLO[4,5 H]IMIDAZO[1,2 C][2,3]BENZODIAZEPINE; 5 PHENYL 8,9 DIMETHYL 11H 1,3 DIOXOLO[4,5 H]IMIDAZO[1,2 C][2,3]BENZODIAZEPINE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; [[3,4 DIHYDRO 7 MORPHOLINO 2,3 DIOXO 6 (TRIFLUOROMETHYL) 1(2H) QUINOXALINYL]METHYL]PHOSPHONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; BENZODIAZEPINE DERIVATIVE; KAINIC ACID; UNCLASSIFIED DRUG; ZK 187638;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BRAIN INFARCTION; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SYNTHESIS; HIPPOCAMPUS; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; RAT; RECEPTOR UPREGULATION;

ACUTE DISEASE; ANIMALS; BENZODIAZEPINES; BINDING, COMPETITIVE; BRAIN INFARCTION; CELLS, CULTURED; DIOXOLES; HIPPOCAMPUS; ISCHEMIC ATTACK, TRANSIENT; KAINIC ACID; MALE; MICE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PATCH-CLAMP TECHNIQUES; PROSENCEPHALON; RADIOLIGAND ASSAY; RATS; RATS, INBRED F344; RECEPTORS, AMPA;

EID: 22244493337     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0580003     Document Type: Article

References (30)

1. Dirnagl, U.; Iadecola, C.; Moskowitz, M. A. Pathobiology of ischaemic stroke: an integrated review. Trends Neurosci. 1999, 22, 391-397.
2. Groom, A. J.; Smith, T.; Turski, L. Multiple sclerosis and glutamate. Ann. N.Y. Acad. Sci. 2003, 993, 229-275.
3. Lees, G. J. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs 2000, 59, 33-78.
4. Takahashi, M.; Ni, J. W.; Kawasaki-Yatsugi, S.; Toya, T.; Ichiki, C.; Yatsugi, S.-I.; Koshiya, K.; Shimizu-Sasamata, M.; Yamaguchi, T. Neuroprotective efficacy of YM872, an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats. J. Pharmacol. Exp. Ther. 1998, 287, 559-566.
5. Donevan, S. D.; Rogawski, M. A. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 1993, 10, 51-59.
6. Backhauss, C.; Karkoutly, C.; Welsch, M.; Krieglstein, J. A mouse model of focal cerebral ischemia for screening neuroprotective drug effects. J. Pharm. Methods 1992, 27, 27-32.
7. Elger, B.; Hornberger, W.; Schwarz, M.; Seega, J. MRI study on delayed ancrod therapy of focal cerebral ischaemia in rats. Eur. J. Pharmacol. 1997, 336, 7-14.
8. Sherman, D. G.; Atkinson, R. P.; Chippendale, T.; Levin, K. A.; Ng, K.; Futrell, N.; Hsu, C. Y.; Levy, D. E. For the STAT participants. Intravenous ancrod for treatment of acute ischemic stroke. JAMA, J. Am. Med. Assoc. 2000, 283, 2395-2403.
9. Solyom, S.; Tarnawa, I. Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Curr. Pharm. Des. 2002, 8, 913-939.
10. Grassp, S.; Micale, N.; Zappala, M.; Galli, A.; Costagli, C.; Menniti, F. S.; De Micheli, C. Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 443-446.
11. Sauter, A.; Rudin, M. Strain-dependent drug effects in rat middle cerebral artery occlusion model of stroke. J. Pharmacol. Exp. Ther. 1995, 274, 1008-1013.
12. Sheardown, M. J.; Nielsen, E. O.; Hansen, A. J.; Jacobsen, P.; Honore, T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline: A neuroprotectant for cerebral ischemia. Science 1990, 247, 571-574.
13. Wood, N. I.; Rothaul, A. L.; Meakin, J. E.; Hunter, A. J. NBQX reduces lesion volume in a rat model of focal cerebral ischemia. Br. J. Pharmacol. 1993, 108 (Suppl.), 265P.
14. Gitto, R.; Orlando, V.; Quartarone, S.; De Sarro, G.; De Sarro, A.; Russo, E.; Fereri, G.; Chimirri, A. Synthesis and evaluation of pharmacological properties of novel annelated 2,3-benzodiazepine derivatives. J. Med. Chem. 2003, 46, 3758-3761.
15. Fujii, T.; Tashiro, M.; Ohara, K.; Kunai, M. The preparation of 3,4-dimethoxy- and 3,4-methylendioxy-phenethylalcohol. Chem. Pharm. Bull. 1960, 8, 266-269.
16. Weinstein, C.; Craig, A. R. A synthetic approach to the cephalotoxine skeleton. J. Org. Chem 1976, 41, 875-878.
17. Bradshaw, D. P.; Jones, D. W.; Tideswell, J. 2-Benzopyran-3-ones, stabilised by alkoxy-substituents, J. Chem. Soc., Perkin Trans. 1 1991, 169-173.
18. De Sarro, A.; de Sarro, G.; Giotto, R.; Grasso, S.; Silvana, N.; Zappala, M. Synthesis and anticonvulsant activity of new 2,3-benzodiazepines as AMPA receptor antagonists. Farmaco 1999, 54 (3), 178-187.
19. Wang, Y.; Konkoy, C. S.; Ilyin, V. I.; Vanover, K. E.; Carter, R. B.; Weber, E.; Keana, J. F. W.; Woodward, R. M.; Cai, S. X. Synthesis of 7,8-(methylenedioxy)-l-phenyl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones as novel and potent noncompetitive AMPA receptor antagonists. J. Med. Chem. 1998, 41 (14), 2621-2625.
20. Grasso, S.; de Sarro, G.; de Sarro, A.; Nicale, N.; Zappala, M.; Pina, G.; Baraldi, M.; de Micheli, C. Synthesis and anticonvulsant activity of novel and potent 2,3-benzodiazepine AMPA/kainate receptor antagonists. J. Med. Chem. 1999, 42 (21), 4414-4421.
21. Reader, V. A. An efficient synthesis of 2-(methylaminomethyl)-4,5- dialkyl-1H-imidazoles. Synlett 1998, 10, 1077-1078.
22. Adachi, J.; Sato, N. Studies on pyrazines. I. The synthesis of 2,3-dihydropyrazines and their derivatives. J. Org. Chem. 1972, 37, 221-225.
23. Baron, B. M.; Harrison, B. L.; Kenne, J. H.; Schmidt, C. J.; Van Giersbergen, P. L.; White, H. S.; et al. Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur. J. Pharmacol. 1997, 323, 181-192.
24. Hall, R. A.; Kessler, M.; Lynch, G. Kainate binding to the AMPA receptor in rat brain. Neurochem. Res. 1994, 19, 777-782.
25. Lehmann, J.; Hutchinson, A. J.; McPherson, S. E.; Mondadori, C.; Schmutz, M.; Sinton, C. M.; et al. CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist. J. Pharmacol. Exp. Ther. 1988, 246, 65-75.
26. 3H]AMPA to non-chaotrope, non-detergent treated rat synaptic membranes: Characteristics and lack of effect of barbiturates. Neurochem. Int. 1991, 18, 75-84.
27. Tamura, A.; Graham, D. I.; McCulloch, J.; Teasdale, G. M. Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 1981, 1, 53-60.
28. Elger, B.; Seega, J.; Raschack, M. Oedema reduction by levemopamil in focal cerebral ischemia of spontaneously hypertensive rats studied by magnetic resonance imaging. Eur. J. Pharmacol. 1994, 254, 65-71.
29. Gundersen, H. J. G.; Bendtsen, T. F.; Korbo, L.; Moller, A.; Nielsen, K.; Nyengaard, J. R.; Pakkenberg, B.; Sorensen, F. B.; Vesterby, A.; West, M. J. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. Acta Pathol., Microbiol. Immunol. Scand. 1988, 96, 379-304.
30. Sager, T. N.; Hansen, A. J.; Laursen, H. Correlation between N-acetylaspartate levels and histopathologic changes in cortical infarcts of mice after middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 2000, 20, 780-788.